Results 61 to 70 of about 586,923 (192)

Kinetic measurements of membrane target level and on-cell binding of biotherapeutic antibodies using flow-cytometry

AAPS Open
Characterization of cell surface target expression is critical for the development of therapeutics that bind membrane proteins or use changes in target abundance as efficacy biomarkers.
Daniel T. Doty, Mahua Roy, Phanidhar Kukutla, Nicholas Lucarelli, Peter E. Struss, Lindsay E. King, Jeffrey R. Chabot, Jatin Narula, Hendrik Neubert, Polina Goihberg   +9 more
doaj   +1 more source

Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model

Clinical and Translational Science, 2020
In the development of new drugs, the prediction of metabolite‐to‐parent plasma exposure ratio in humans prior to administration in a clinical study has emerged as an important need.
Ernesto Callegari, Manthena V.S. Varma, R. Scott Obach   +2 more
doaj   +1 more source

Pharmacokinetic study of praziquantel enantiomers and its main metabolite R-trans-4-OH-PZQ in plasma, blood and dried blood spots in Opisthorchis viverrini-infected patients [PDF]

, 2016
Praziquantel (PZQ) is the treatment of choice for infections with the liver fluke Opisthorchis viverrini, a major health problem in Southeast Asia. However, pharmacokinetic (PK) studies investigating the disposition of PZQ enantiomers (R- and S-PZQ) and ...
Duthaler, Urs, Huwyler, Jörg, Keiser, Jennifer, Kovac, Jana, Meister, Isabel, Odermatt, Peter, Sayasone, Somphou, Vanobberghen, Fiona   +7 more
core   +2 more sources

Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor

Infectious Diseases and Therapy
Introduction Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19.
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota   +3 more
doaj   +1 more source

Development of a SARS‐CoV‐2 viral dynamic model for patients with COVID‐19 based on the amount of viral RNA and viral titer

CPT: Pharmacometrics & Systems Pharmacology
The target‐cell limited model, which is one of the mathematical modeling approaches providing a quantitative understanding of viral dynamics, has been applied to describe viral RNA profiles of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota   +2 more
doaj   +1 more source

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. [PDF]

, 2011
Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and exposure-response relationships remain undefined.
Brunstein, CG, Cao, Q, Green, KG, Jacobson, PA, Long-Boyle, JR, McGlave, PB, Miller, JS, Rogosheske, J, Wagner, JE, Weisdorf, DJ   +9 more
core   +1 more source

The heterogeneity among subgroups of haplogroup J influencing Alzheimer’s disease risk

Journal of Advanced Research, 2021
Introduction: The impact of mitochondrial haplogroups on Alzheimer’s disease (AD) risk has not been fully elucidated and warrants further investigation at the subgroup level.
HaoChen Liu, Yixuan Zhang, Huimin Zhao, Yanan Du, XiaoQuan Liu   +4 more
doaj  

Pyridoxic Acid as Endogenous Biomarker of Renal Organic Anion Transporter Activity: Population Variability and Mechanistic Modeling to Predict Drug–Drug Interactions

CPT: Pharmacometrics & Systems Pharmacology
Pyridoxic acid (PDA) was suggested as a potential endogenous biomarker to assess in vivo renal organic anion transporter (OAT) 1 and 3 activity. Here, we first investigated the population variability in the plasma baseline levels of PDA using data from ...
Aarzoo Thakur, Sumathy Mathialagan, Emi Kimoto, Manthena V. S. Varma   +3 more
doaj   +1 more source

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

Journal of Immunology Research, 2015
Therapeutic protein products (TPP) have been widely used to treat a variety of human diseases, including cancer, hemophilia, and autoimmune diseases. However, TPP can induce unwanted immune responses that can impact both drug efficacy and patient safety.
Liusong Yin, Xiaoying Chen, Abhinav Tiwari, Paolo Vicini, Timothy P. Hickling   +4 more
doaj   +1 more source

Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia

Pharmacology Research & Perspectives
We investigated the metabolism and disposition of vornorexant, a novel dual orexin receptor antagonist, in rats and dogs, and clarified in vitro metabolite profiles in humans.
Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, Shuichi Terasaka, Hirohiko Hikichi, Hiromi Endo, Jun‐Ichi Yamaguchi, Akiko Mizuno‐Yasuhira   +7 more
doaj   +1 more source